Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
13.54
+0.28 (2.11%)
Nov 4, 2024, 4:00 PM EST - Market closed
Avalo Therapeutics Analyst Ratings
Total Analysts
2
Consensus Rating
Buy
Price Target
$35.00
Upside
+158.49%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 24, 2024 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $35 | Hold → Buy | Upgrades | $35 | +158.49% | Apr 16, 2024 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 27, 2023 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $2,160 → $180 | Buy → Hold | Downgrades | $2,160 → $180 | +1,229.39% | Jun 27, 2023 |
| RBC Capital | RBC Capital | Buy Maintains $4,080 → $2,160 | Buy | Maintains | $4,080 → $2,160 | +15,852.73% | May 10, 2023 |
| Jefferies | Jefferies | Hold → Sell Downgrades $720 | Hold → Sell | Downgrades | $720 | +5,217.58% | Feb 8, 2023 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $14,400 → $2,160 | Strong Buy → Hold | Downgrades | $14,400 → $2,160 | +15,852.73% | Mar 3, 2022 |
| RBC Capital | RBC Capital | Buy Maintains $14,400 → $11,520 | Buy | Maintains | $14,400 → $11,520 | +84,981.24% | Mar 3, 2022 |
| RBC Capital | RBC Capital | Buy Initiates $17,280 | Buy | Initiates | $17,280 | +127,521.86% | Sep 24, 2021 |